Item 4. MINE SAFETY DISCLOSURES.

Not applicable.

PART IA

Information about our Executive Officers

Listed below is information on our executive officers as of February 11, 2026. Executive officers are elected by the Board of Directors for an initial term, which continues until the first Board meeting following the next Annual Meeting of Shareholders, and thereafter, are elected for a one-year term or until their successors have been elected. Executive officers serve at the discretion of the Board of Directors.


Name and Current Position	Age	Employment History
Christopher Boerner, Ph.D. Chair of the Board and Chief Executive Officer Member of the Leadership Team	55	2015 to 2017 – President and Head of U.S. Commercial 2017 to 2018 – President and Head, International Markets 2018 to 2023 – Executive Vice President, Chief Commercialization Officer 2023 to 2023 – Executive Vice President, Chief Operating Officer 2023 to 2024 – Chief Executive Officer 2024 to present – Chair of the Board and Chief Executive Officer
David V. Elkins Executive Vice President and Chief Financial Officer Member of the Leadership Team	57	2014 to 2017 – Group Vice President and Chief Financial Officer, Consumer and Consumer Medicines, Johnson & Johnson 2017 to 2018 – Worldwide Vice President and Chief Financial Officer, Consumer Products, Medical Development and Corporate Functions, Johnson & Johnson 2018 to 2019 – Chief Financial Officer, Celgene Corporation 2019 to present – Executive Vice President and Chief Financial Officer
Cari Gallman Executive Vice President, General Counsel and Chief Policy Officer Member of the Leadership Team	46	2015 to 2018 – Senior Counsel, US Legal 2018 to 2019 – Assistant General Counsel, Oncology Legal 2019 to 2021 – Vice President, Assistant General Counsel, Worldwide Oncology 2021 to 2023 – Senior Vice President, Chief Compliance Officer 2023 to 2025 – Executive Vice President, Corporate Affairs 2025 to present - Executive Vice President, General Counsel and Chief Policy Officer
Benjamin Hickey President, RayzeBio Organization Member of the Leadership Team	51	2014 to 2016 – Vice President, Commercial, Immuno-Oncology 2016 to 2018 – General Manager, UK & Ireland 2018 to 2020 – Senior Vice President, Chief Commercial Officer, Halozyme Therapeutics 2020 to 2024 – Chief Commercial Officer, Head of Business Development, Mirati Therapeutics 2024 to present – President, RayzeBio Organization, Bristol-Myers Squibb Company
Lynelle Hoch President, Cell Therapy Organization Member of the Leadership Team	53	2016 to 2019– Vice President, Immuno-Oncology Marketing 2019 to 2021 – General Manager, Ireland & UK, Major Markets 2021 to 2023 – Senior Vice President, Global Cell Therapy Franchise Lead 2023 to present – President, Cell Therapy Organization
Phil Holzer Senior Vice President & Controller	50	2015 to 2018 – Chief Audit Officer 2018 to 2019 – Vice President & Head of Finance, Research & Development 2019 to 2021 – Senior Vice President, Enterprise Integration Management 2021 to 2024 – Senior Vice President, Finance, Tax & Treasury 2024 to present – Senior Vice President & Controller
Adam Lenkowsky Executive Vice President, Chief Commercialization Officer Member of the Leadership Team	54	2016 to 2019 – Head of US Oncology 2019 to 2022 – Senior Vice President, General Manager of U.S. Oncology, Immunology & Cardiovascular 2022 to 2023 Senior Vice President, Head of Major Markets 2023 to present – Executive Vice President, Chief Commercialization Officer
Cristian Massacesi, M.D. Executive Vice President, Chief Medical Officer, Head of Development Member of the Leadership Team	57	2019 to 2020 – Senior Vice President, Head of Oncology Late Development, Astra Zeneca 2021 to 2025 – Chief Medical Officer, Oncology Chief Development Officer, AstraZeneca 2025 to present – Executive Vice President, Chief Medical Officer, Head of Development
Greg Meyers Executive Vice President, Chief Digital and Technology Officer Member of the Leadership Team	53	2014 to 2018 – Corporate Vice President and Chief Information Officer, Motorola Solutions 2018 to 2022 – Group Chief Information and Digital Officer, Syngenta Group 2022 to present – Executive Vice President, Chief Digital and Technology Officer
Robert Plenge, M.D., Ph.D. Executive Vice President, Chief Research Officer, Head of Research Member of the Leadership Team	55	2017 to 2019 – Vice President Inflammation and Immunology, Thematic Center of Excellence Unit, Celgene Corporation 2019 to 2021 – Senior Vice President, Immunology, Cardiovascular & Fibrosis, Thematic Research Center 2021 to 2023 – Senior Vice President, Immunology, Cardiovascular & Fibrosis, Thematic Research Center, and Head of Translational Medicine 2023 to 2023 – Senior Vice President and Head of Discovery and Translational Sciences 2023 to present – Executive Vice President, Chief Research Officer, Head of Research
Amanda Poole Executive Vice President, Chief People Officer Member of the Leadership Team	51	2017 to 2019 – Vice President, Head of Human Resources, Global Product Development & Supply 2019 to 2020 – Vice President, Head of BMS/Celgene Integration 2020 to 2022 – Senior Vice President, Head of Human Resources, Commercialization 2022 to 2024 – Senior Vice President, People Strategy, Solutions & Services 2024 to present – Executive Vice President, Chief People Officer
Karin Shanahan Executive Vice President, Chief Supply Chain & Operations Member of the Leadership Team	61	2013 to 2018 – Senior Vice President and Chief Operating Officer, Global Operations, Teva Pharmaceuticals 2018 to 2022 – Senior Vice President, Global Biologics & Sterile Operations, Merck 2022 to present – Executive Vice President, Chief Supply Chain & Operations Officer


Name and Current Position	Age	Employment History
Hiroshi Chris Shibutani, M.D. Executive Vice President, Chief Strategy Officer Member of the Leadership Team	62	2015 to 2020 – Senior Analyst, Managing Director, Biotechnology Equity Research, Cowen 2021 to 2025 – Senior Analyst, Managing Director, Pharmaceuticals & Biotechnology Equity Research, Goldman Sachs 2025 to present – Executive Vice President, Chief Strategy Officer
Wendy Short Bartie Executive Vice President, Corporate Affairs Member of the Leadership Team	54	2021 to 2022 – Senior Vice President, U.S. Oncology 2022 to 2023 – Senior Vice President, Chief of Staff to the CEO 2023 to 2023 – Senior Vice President, General Manager, US Hematology and Cell Therapy 2024 to 2025 – Senior Vice President, U.S. Oncology and Hematology 2025 to 2025 – Senior Vice President, Oncology Commercialization 2025 to present – Executive Vice President, Corporate Affairs

PART II

Previous: Item 3. LEGAL PROCEEDINGS. · Next: Item 5. MARKET FOR THE REGISTRANT’S COMMON EQUITY, RELATED STOCKHOLDER MATTERS AND ISSUER PURCHASES OF EQUITY SECURITIES.